Turning a Popular Smartwatch into a Muscle Loss Early-Warning System
Samsung’s Galaxy Watch muscle loss initiative is a clinical study exploring whether data from the Galaxy Watch8 can help doctors spot harmful lean-mass decline in people taking GLP-1 weight-loss drugs, comparing smartwatch tracking against standard medical care and clinical body-composition scans. At the center is a collaboration with Massachusetts General Hospital’s Diabetes Research Center, which is following adults who are starting GLP-1 treatments such as Ozempic-style medications. One group receives standard guidance and follow-up, while another is equipped with a Galaxy Watch8 and the Samsung Health app. Those smartwatch users will track body composition, physical activity, and heart rate, and receive in-app exercise guidance. Researchers will then compare outcomes against DXA scans, a clinical gold standard for body composition, to see whether continuous, wrist-based data adds meaningful insight beyond the bathroom scale and periodic office visits.
Why GLP-1 Weight Loss Needs Better Tracking Than a Scale
GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound have reset expectations for rapid weight loss, but the scale alone cannot tell what kind of tissue is disappearing. Muscle loss alongside fat loss can lower strength, reduce basal metabolic rate, and make long-term weight maintenance harder. Dr. Melissa Putman, director of the Mass General Diabetes Research Center, notes that many GLP-1 patients struggle with muscle loss and describes it as “a common side effect” with potential cardiovascular consequences. Weekly weigh-ins can show progress while masking a decline in lean mass that affects how patients feel and function. By tying weight loss tracking to continuous activity, sleep, and heart rate data, the Galaxy Watch8 trial aims to highlight when weight is dropping too fast or without enough physical activity support, giving clinicians an earlier chance to adjust exercise plans, nutrition, or dosing.
How Galaxy Watch8 Data Could Reveal Hidden Muscle Loss
The study focuses on whether data points already collected by consumer wearables can support GLP-1 drug monitoring in a more clinical way. In the Galaxy Watch8 group, participants will record body composition, track daily steps and workouts, and log sleep and stress-related metrics through Samsung Health. Shifts in these metrics can indirectly reflect how well patients are preserving muscle during weight loss; for example, stable or increasing activity levels paired with healthier sleep patterns may support better lean-mass retention than sedentary weight loss. DXA scans will serve as the benchmark, so any wearable-derived indicators of muscle loss can be checked against precise clinical measurements rather than accepted at face value. The goal is not to replace medical imaging, but to see whether changes in routine smartwatch data can act as early signals that it is time to reassess a patient’s treatment plan.
From Consumer Gadget to Wearable Clinical Research Tool
By partnering with Mass General, Samsung is testing whether a mainstream smartwatch can support wearable clinical research instead of staying in the fitness-only lane. Nearly one in five adults report they have taken a GLP-1, according to KFF polling, which makes continuous monitoring a growing challenge for clinicians who see patients only a few times per year. A smartwatch cannot replace lab work, imaging, or medical judgment, and Samsung is clear that Galaxy Watch8 readings are not meant to diagnose or treat disease. Still, daily data streams may help fill in the gaps between visits, especially for specialized health conditions such as GLP-1–driven weight loss. If the study shows that Galaxy Watch muscle loss patterns correlate with DXA results, future care models could routinely pair prescription weight-loss drugs with wearable-based monitoring and targeted exercise coaching.
